Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hematologist

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Hematologist. Displaying page 1 of 1.
    EudraCT Number: 2022-003265-38 Sponsor Protocol Number: PTC743-NEU-005-FA Start Date*: 2022-10-22
    Sponsor Name:PTC Therapeutics, Inc.
    Full Title: An Open-Label Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Vatiquinone in Children With Friedreich Ataxia Younger Than 7 Years of Age
    Medical condition: Friedreich Ataxia
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2015-003775-30 Sponsor Protocol Number: CICL670ABE04 Start Date*: 2016-01-18
    Sponsor Name:Novartis Pharma NV
    Full Title: A phase II pilot study to assess the presence of molecular factors predictive for hematologic response in myelodysplastic syndrome patients receiving deferasirox therapy in hematological centers in...
    Medical condition: The study will include two groups of patients with low and intermediate 1 risk myelodysplastic syndrome. One group consists of patients who experience an hematological response while on deferasirox...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002885-30 Sponsor Protocol Number: ARES Start Date*: 2017-07-27
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Novel strategies of antithrombotic prophylaxis in patients with Essential Thrombocythemia (ET) at high risk of cardiovascular events: comparison of different dosing regimens of administration of l...
    Medical condition: Essential thrombocytemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015493 Essential thrombocythaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003710-13 Sponsor Protocol Number: NL41820.018.12 Start Date*: 2013-03-21
    Sponsor Name:Academic Medical Center
    Full Title: C1-inhibitor improves efficacy of red blood cell transfusion in patients suffering from autoimmune hemolytic anemia – an open-labeled pilot trial
    Medical condition: AutoImmune Hemolytic Anemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10003825 Autoimmune hemolytic anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001477-33 Sponsor Protocol Number: 071102 Start Date*: 2016-12-01
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF with or without ADVATE in the Treatment and Control of Bleed...
    Medical condition: Hereditary severe von Willebrand Disease in children
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10055168 Von Willebrand's factor deficiency LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) IT (Trial now transitioned) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) CZ (Completed) ES (Trial now transitioned) FR (Trial now transitioned) DE (Completed) NL (Completed) Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2017-004539-36 Sponsor Protocol Number: 16NC06 Start Date*: 2020-05-19
    Sponsor Name:Great Ormond Street Hospital for Children NHS Foundation Trust
    Full Title: Study of Montelukast In Children with Sickle Cell Disease (SMILES)
    Medical condition: Sleep-disordered breathing
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10078294 Obstructive sleep apnoea hypopnoea syndrome LLT
    21.0 100000004855 10040977 Sleep apnoea LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-003124-44 Sponsor Protocol Number: DKMS-14-01 Start Date*: 2015-01-15
    Sponsor Name:DKMS gemeinnützige GmbH
    Full Title: Evaluation of the impact of remission induction chemotherapy prior to allogeneic stem cell transplantation in relapsed and poor-response patients with AML
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10024349 Leukemia myeloid LLT
    20.1 100000004864 10024330 Leukemia acute LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-002515-34 Sponsor Protocol Number: CMG012022 Start Date*: 2023-03-28
    Sponsor Name:Czech Myeloma Group
    Full Title: Phase 2 study of belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Medical condition: The study will enroll adult participants with RRMM who have been previously treated with at least 1 prior line of therapy, and who have documented disease progression during, or after, their most r...
    Disease: Version SOC Term Classification Code Term Level
    25.0 100000004864 10086466 Relapsed/refractory multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000673-83 Sponsor Protocol Number: TJB2101 Start Date*: 2021-03-11
    Sponsor Name:CHU de Liège
    Full Title: Impact of the immune system on response to COVID-19 vaccine in allogeneic stem cell recipients
    Medical condition: Allogeneic hematopoietic stem cell recipients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004554-14 Sponsor Protocol Number: PIX111 Start Date*: 2016-11-24
    Sponsor Name:CTI BioPharma Corp.
    Full Title: A Phase 1, Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients with Relapsed or Refractory Cancer
    Medical condition: Relapsed or refractory solid tumors (excluding those with CNS tumors) or lymphoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10007050 Cancer LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2020-002812-36 Sponsor Protocol Number: PTC743-NEU-003-FA Start Date*: 2021-02-18
    Sponsor Name:PTC Therapeutics, Inc.
    Full Title: A Randomized, Parallel-Arm, Double-Blind, Placebo-Controlled Study with Open-Label Extension to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Friedreich ataxia (MOVE-FA)
    Medical condition: Friedreich Ataxia (FA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10017374 Friedreich's ataxia PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) FR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 11:43:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA